China’s Hengrui Pharma Advances in Global Obesity Drug Race with Promising Results for HRS9531
A new contender in the global weight-loss drug market is emerging from China. Jiangsu-based Hengrui Pharma, together with its U.S. partner Kailera Therapeutics, has announced encouraging late-stage trial results for HRS9531, an investigational obesity treatment showing comparable efficacy to leading therapies on the market. In a 48-week Phase 3 trial, patients on HRS9531 lost an […]